Osiris strikes deal to sell marquee stem cell drug for $100M – Baltimore Sun
|
Osiris strikes deal to sell marquee stem cell drug for $100M
Baltimore Sun Columbia biotechnology company Osiris Therapeutics has reached a deal to sell its marquee stem cell drug, the first to win government approval, for up to $100 million. A subsidiary of Australian company Mesoblast Ltd. has agreed to pay $50 million for … |
